Alliance Pharma PLC Correction: Application for admission (6283E)

TIDMAPH

RNS Number : 6283E

Alliance Pharma PLC

09 May 2017

 
 For immediate release   9 May 2017 
 

The following amendment has been made to the "Application for admission" announcement released on 8 May 2017 at 2.30pm under RNS 4932E:

Application has been made for 66,815 ordinary shares to be admitted to AIM rather than the 66,315 previously stated. All other details remain unchanged.

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Application for admission

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that following the exercise of employee share options, application has been made by Alliance for a further 66,815 ordinary shares of 1p each in the Company ("Ordinary Shares") to be admitted to trading on AIM.

It is expected that these new Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares, will be admitted to trading on 12 May 2017.

After admission, Alliance will have 472,963,997 Ordinary Shares in issue.

For further information:

 
 Alliance Pharma plc                             + 44 (0) 1249 466966 
 John Dawson, Chief Executive 
  Andrew Franklin, Chief Financial 
  Officer 
 Rob Bellhouse, Company Secretary 
 www.alliancepharma.co.uk 
                                                     + 44 (0) 20 7466 
  Buchanan                                                       5000 
 Mark Court / Sophie Cowles 
  / Jane Glover 
 
                                                     + 44 (0) 20 7260 
 Numis Securities Limited                                        1000 
 Nominated Adviser: Michael 
  Meade / Freddie Barnfield 
 Corporate Broking: James 
  Black / Toby Adcock 
 

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ALSBDGDUBXGBGRC

(END) Dow Jones Newswires

May 09, 2017 08:50 ET (12:50 GMT)